AI Summary

A cluster‑randomized trial examined the effect of moving HPV vaccine initiation from ages 11‑12 to ages 9‑10 in 31 pediatric practices across Colorado and California between 2021 and 2026. Sixteen practices were assigned to start the series at 9‑10 years, while 15 continued the standard 11‑12‑year schedule. The study, presented at IDWeek in Washington, D.C., found that earlier introduction led to a meaningful increase in both initiation and completion of the vaccine series, including higher rates of completion by age 13. Sean O’Leary, M.D., M.P.H., and colleagues reported these findings at the Infectious Diseases Society of America meeting.

AI summaries can be wrong sometimes—always verify important details using the source article.